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Executive Summary 
 
 
 
 
 
 
 
 
 
 
 
Total Capital Investment $ 92,377,000 
Operating Costs $37,045,000 
Revenues $ 80,495,000 
Benefits $ 43,450,000 
Unit Production Cost 4.60 $/Entity 
Unit Production Revenue 10 $/Entity 
Payback Time 3.08 years 
IRR 27.58 % 
NPV (7%) $ 138,762,000 
Total Capital Investment 
 
 
 
 
 
 
 
 
 
Cash Flow 
 
 
 
 
 
 
 
 
 
 
ENVIRONMENTALLY  
SUSTAINABLE PROCESS 
Potentially dangerous streams: 
· Air inputs and outputs HEPA filters  
· Wastes from GMP process NaOH inactivation and HCl neutralization 
Air and Water are the major inputs required, while 
Emissions and Water are the major outputs obtained 
Tris HCl, NaOH and HCl are the most 
hazardous components for the environment; 
followed by N2 liquid, Biomass and Viruses 
 
 
 
· Horses health improved 
· Innovation in the existing production 
  system 
· Strong acceptance among the society 
· Optimal security measures and  
  process automation 
· Quality work respecting international 
  standards 
· Active competition among operators  
  and high salary 
· GMP product 
 
 
 
 
 
SOCIALLY ACCEPTABLE PROCESS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Simultaneous expression of 2 proteins of interest 
thanks to: 
· 2 strong promoters in opposite direction    
  (p10 and polyhedrin) 
· 2 multiple cloning sites for large inserts 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VACCINATION CAMPAIGN 
Take advantage of the 8 months of 
inactivity to produce more vaccines 
for the equine sector 
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Design of an industrial bioprocess plant with the simulator SuperPro Designer for 
the production of the equine influenza vaccine using a baculovirus expression 
system in insect cell lines, and subsequent analysis of its sustainability. 
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 Low-cost and rapid production of proteins 
 Correctly folded and biologically active 
proteins 
 GMP-qualified master virus banks and cell line 
 Scalable to large volumes and high cell 
densities 
 Platform for the development of a wide range 
of vaccines 
Advantages BEVS 
 Reliable 
 Effective 
 Affordable 
Χ High production time 
Χ Heavily dependent on eggs 
Χ Possible allergic reactions 
Egg-derived vaccines 
 
 Serum-free, low cost media 
 High density growth 
 Duplication time: 18-24h 
 Viral production 48-72h post-infection 
 
 High virus titres 
 High production of recombinant proteins 
 Scalable for GMP manufacturing 
 No aggregation 
 
 
Improvements 
· High initial investment 
· Short period recovery: 3.08 years from the production start time 
· Adjustable market price 
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ECONOMICS COMPARISON 
Cost optimization and higher benefits 
New type of cells: ExpresSF+ 
Use of a pFastbacTM Dual expression vector 
Multi-process industry 
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